FOCAL POINTS (Courageous Discourse)

FOCAL POINTS (Courageous Discourse)

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Persistent Myocarditis, Neuropathy, Coagulopathy Years after Pfizer-BioNTech COVID-19 Vaccination

Persistent Myocarditis, Neuropathy, Coagulopathy Years after Pfizer-BioNTech COVID-19 Vaccination

Long-Term, Multisystem Damage Requires Tremendous Diagnostic and Treatment Response

Peter A. McCullough, MD, MPH's avatar
Peter A. McCullough, MD, MPH
Apr 07, 2024
∙ Paid
141

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Persistent Myocarditis, Neuropathy, Coagulopathy Years after Pfizer-BioNTech COVID-19 Vaccination
18
10
Share
Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

Every serious adverse event after mRNA vaccination is a new learning opportunity for doctors studying this novel, injected, disease-creating biotechnology.

Finsterer reported a tragic case of a 51 year old female who had complications involving the cardiovascular, neurologic, and hematologic systems that were devastating. There were many impressive features in this case including the long period of time from the first injection (December, 2021) to continued clinical manifestations requiring treatment (January, 2024).

As you can see her complications were severe and required intensive diagnostics and therapeutics. Likely she was disabled from vaccination with damage to nerves serving her face, vocal cords, limbs and sensation.

Finsterer reveals the intensity of his diagnostics and the wide array of findings suggesting Epstein Barr Virus reactivation, partial myasthenia gravis, and autoimmunity.

Keep reading with a 7-day free trial

Subscribe to FOCAL POINTS (Courageous Discourse) to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share